BridgeMD
New treatment option for Testicular Cancer
Official title A Clinical Trial of Primary Retroperitoneal Lymph Node Dissection in Patients With Testicular Seminoma With Limited Retroperitoneal Metastases
ClinicalTrials.gov ID: NCT06932458
What this study is testing
- What it's testing
- Testicular cancer represents 1% of adult neoplasms and is the most common solid malignancy in young men. At diagnosis, approximately 90% of cases are germ cell tumours (GCT), categorised as either seminoma (55-60%) or non-seminoma types (40-45%).
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older, men only
You may be able to join if
- Adult patients (\>18 years) with pure seminoma on radical orchiectomy specimen.
- Initial CS I presentation with subsequent retroperitoneal relapse on surveillance, or de novo CS II at presentation.
- Axial imaging of lymphadenopathy within 8 weeks of the date of RPLND
- No more than 2 enlarged retroperitoneal lymph nodes, each no more than 3cm in the primary landing zones.
- Suitable for proposed bilateral RPLND template
You likely can't join if
- Any condition deemed by the treating surgeon to pose an unacceptable risk for retroperitoneal lymph node dissection
- Any non-seminoma component on the orchiectomy specimen.
- AFP \>20 at any time point, pre- or post-orchiectomy.
See the full eligibility criteria
- Adult patients (\>18 years) with pure seminoma on radical orchiectomy specimen.
- Initial CS I presentation with subsequent retroperitoneal relapse on surveillance, or de novo CS II at presentation.
- Axial imaging of lymphadenopathy within 8 weeks of the date of RPLND
- No more than 2 enlarged retroperitoneal lymph nodes, each no more than 3cm in the primary landing zones.
- Suitable for proposed bilateral RPLND template
- Serum tumour markers (alpha-fetoprotein (AFP), human chorionic gonadotropin (HCG), and lactate dehydrogenase (LDH)) must all be within normal limits within 2 weeks of planned RPLND
- Any condition deemed by the treating surgeon to pose an unacceptable risk for retroperitoneal lymph node dissection
- Any non-seminoma component on the orchiectomy specimen.
- AFP \>20 at any time point, pre- or post-orchiectomy.
The study team makes the final eligibility decision.
Where it's taking place
- London, Ontario, Canada
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling male, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include London, Ontario, Canada. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.